The Institute of Health Carlos III has funded the project “Study of rare variants in genes associated with Alzheimer's disease in the Spanish population” in the call Strategic Health Action 2016, File Nº: PI 16/01652 with a budget of 139,150 €. This is a multicenter project coordinated by Dr. Pascual Sánchez-Juan, Neurologist at the Marqués […]
El presentismo es un fenómeno nuevo que se estudia desde principios del año 2000 y se define como la presencia del trabajador en su puesto de trabajo pese a no estar en plenas condiciones físicas o psíquicas lo cual tiene como consecuencia que su rendimiento no es el esperado. Las pérdidas anuales que se podían […]
The Laboratory of Molecular Hematology, led by IDIVAL researcher Carlos Pipaón, has found while working with G418-resistant stably transfected cells, they realized the neomycin resistance gene (NeoR), which encodes the aminoglycoside-3′-phosphotransferase-IIa [APH(3′)-IIa], also confers resistance to the nucleoside analog fludarabine. Fludarabine is a cytostatic drug widely used in the treatment of hematologic and solid tumors […]
Valdecilla brand, created in 1929, has been cited more than 100,000 times by the international biomedical literature, according to data obtained on the Web of Science database. According to these data, papers published by the authors who have in their affiliation the brand Valdecilla (exclusive brand worldwide of our Hospital) have been referenced in more […]
Charcot-Marie-Tooth disease (CMT) is the most common hereditary neuropathy that, according to the values of motor conduction velocity (MCV) of the median nerve (normal, ≥49 m / s), is divided into three basic patterns: i / demyelinating, CMT1 with MCV 38 / m / s (average around 45 m / s); And iii / intermediate, […]
IDIVAL has just published the progress of its annual report summarizing the main milestones and data of activity developed, both in terms of scientific production and economic results. Throughout its 22 pages prologued by the President of the IDIVAL Board of Trustees and Counselor of Health of the Government of Cantabria, Maria Luisa Real, the […]
Institute of Health Carlos III (ISCIII) has granted the research lines of Transplantation and Autoimmunity group at the Health Research and Development Strategy 2016. This group is part of the Health Research Institute Marques de Valdecilla (IDIVAL) and is leaded by the researcher Marcos López Hoyos, Head of the Immunology Department at the HUMV (Marques […]
Group of Infection and Immunity of the Digestive System of IDIVAL led by from Marqués de Valdecilla University Hospital and the University of Cantabria has just joined as a Group linked to CIBER. This Group focuses on the study of viral hepatitis where it has already become a national reference, and in liver fat deposition […]
Animal models of schizophrenia constitute at this moment fundamental experimentation tools to further explore on the etiological basis of this pathology, leading to the discovery of new biological targets and innovative therapeutic strategies for its treatment. Our research group Prof. Dr. Crespo-Facorro, Dr. Juan F. Lopez-Giménez (CSIC) and the research team of Prof. Dr. Gonzalez-Maeso […]
Institute of Health Carlos III granted the project “Targeted exonic next generation sequencing for the molecular diagnosis and cell free tumor DNA analysis as screening method for patients with DLBCL” in the call for grants Health Research and Development Strategy 2016 File Nº: PI16/01397 with the amount of 98.615€. The research project is led by Dr. Santiago […]
